| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5929048 | FOUGERA PHARMS | Treatment of conditions and disease |
Jun, 2014
(9 years ago) | |
| US5639738 | FOUGERA PHARMS | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
Jun, 2014
(9 years ago) | |
| US5852002 | FOUGERA PHARMS | Treatment of conditions and disease |
Jun, 2014
(9 years ago) | |
| US5914322 | FOUGERA PHARMS | Treatment of disease and conditions |
Aug, 2015
(8 years ago) | |
| US5985850 | FOUGERA PHARMS | Compositions comprising hyaluronic acid and drugs |
Aug, 2015
(8 years ago) | |
| US5792753 | FOUGERA PHARMS | Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs |
Aug, 2015
(8 years ago) | |
Solaraze is owned by Fougera Pharms.
Solaraze contains Diclofenac Sodium.
Solaraze has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Solaraze are:
- US5929048
- US5639738
- US5852002
- US5914322
- US5985850
- US5792753
Solaraze was authorised for market use on 16 October, 2000.
Solaraze is available in gel;topical dosage forms.
Solaraze can be used as treatment of actinic keratoses.
The generics of Solaraze are possible to be released after 11 August, 2015.
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 October, 2000
Treatment: Treatment of actinic keratoses
Dosage: GEL;TOPICAL
How can I launch a generic of SOLARAZE before it's drug patent expiration?
More Information on Dosage
SOLARAZE family patents
